ClinicalTrials.gg
CompletedNCT06698939ORKA-001-111Updated Apr 1, 2026

ORKA-001 in Healthy Volunteers

A Phase 1 interventional study of ORKA-001 and Placebo in Healthy Volunteers, sponsored by Oruka Therapeutics, Inc.. Completed at 1 site in New Zealand. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Oruka Therapeutics, Inc. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a Phase 1, First-in-human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ORKA-001 in Healthy Participants.

Read the detailed description

This is a single center, phase 1, double-blind, placebo-controlled, randomized, first-in-human (FIH), single ascending dose study evaluating the safety, tolerability, and pharmacokinetics (PK) of ORKA-001 in healthy volunteers. The study will enroll approximately 24 healthy volunteers. The ORKA-001 dose will be administered by a subcutaneous injection.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • ORKA-001
  • Phase 1
03

In context

Lead sponsor

Oruka Therapeutics, Inc. is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Healthy male or female participants
  2. 18 to 65 years (inclusive) with a (BMI) 18 to 32 kg/m2
  3. Willing and able to remain at the study site unit for the duration of the confinement period and return for the outpatient visit/s defined in the protocol
  4. Using a highly effective method of from admission through the end of the study.
  5. Willing to abstain from regular, continuous alcohol use or tobacco use as per protocol

Key Exclusion Criteria:

  1. Any medical condition or finding that, in the Investigator's opinion, is likely to unfavorably alter the risk of study participation, confound study results, or interfere with the study conduct or compliance.
  2. Known history of illicit drug use or drug abuse or harmful alcohol use
  3. Known history of frequent tobacco or vaping use within 2 years prior to Screening
  4. History of severe allergic reactions or
  5. Actively nursing or lactating
  6. Use of drug therapy within 30 days prior to enrollment
  7. Unable to comply with study requirements or in the opinion of the Investigator should not participate in this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    ORKA-001

    Participants will receive subcutaneous injection of ORKA-001 at either 300 mg, 600 mg or 1200 mg.

    Drug: ORKA-001

  • Placebo comparator
    Placebo

    Participants will receive a subcutaneous injection of placebo comparator.

    Other: Placebo

Interventions

  • ORKA-001 is supplied as sterile solution to be administered by SC injection

  • OtherPlacebo

    Placebo solution to be administered at a matching volume by SC injection

06

What researchers measure

Primary outcomes

  1. Number and frequency of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Incidence of treatment-emergent adverse events (TEAEs) and clinically significant changes from baseline in vital signs, electrocardiograms (ECGs), clinical laboratory parameters, and physical examinations.

    Time frame: Day 1 through one year

Secondary outcomes

  1. Maximum observed serum concentration of ORKA-001

    CMax of ORKA-001

    Time frame: Day 1 through one year

  2. Time to CMax (TMax) of ORKA-001

    TMax of ORKA-001

    Time frame: Day 1 through one year

  3. Area Under the Serum Concentration-Time Curve (AUC) of ORKA-001

    Area under the curve from the time of dosing to infinity (AUC0-inf)

    Time frame: Day 1 through one year

  4. Terminal elimination half-life (T1/2)

    T1/2 of ORKA-001

    Time frame: Day 1 through one year

07

Study locations

1 site
  • Oruka Therapeutics Investigative Site
    Christchurch, New Zealand
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Mar 2026, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2024
First posted
Nov 21, 2024
StartActual
Dec 19, 2024
Primary completionActual
Mar 13, 2026
CompletionActual
Mar 13, 2026
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06698939
Lead sponsor
Oruka Therapeutics, Inc.
Responsible party
Sponsor
First posted
Nov 21, 2024
Start date
Dec 19, 2024
Primary completion
Mar 13, 2026
Completion
Mar 13, 2026
Last update
Apr 1, 2026

Study contacts

Kyle Breitschwerdt
study director · Oruka Therapeutics, Inc.
Principal Investigator
principal investigator · Oruka Therapeutics Investigative Site

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avrukibart

Start the discussion